Foamix Earns US$ 2.5M Milestone Payment From Bayer HealthCare

Foamix Pharmaceuticals Ltd. FOMX, a clinical-stage specialty pharmaceutical company, announces the receipt of a milestone payment of US$ 2.5 million from Bayer HealthCare. According to a license agreement between the two companies Foamix is entitled to royalties and further milestone payments under certain conditions. Under the agreement, Bayer has licensed from Foamix a foam vehicle for its compound azelaic acid. Terms of the license agreement are not being disclosed. Information regarding a Phase III study of Azelaic Acid Foam 15% may be found at clinicaltrials.gov.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: NewsPress Releases
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!